News
Sarepta Therapeutics (NasdaqGS:SRPT) SRP-9003 Gene Therapy Earns FDA Platform Technology Designation
Sarepta Therapeutics (NasdaqGS:SRPT) recently announced that its SRP-9003 gene therapy received a platform technology designation from the FDA, and updated safety protocols for ELEVIDYS in the UK.
WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in ...
Diaylsis-technology maker Fresenius Medical Care could end up benefiting from blockbuster obesity drugs, according to its chief executive, contrary to concerns that such treatments could deplete ...
The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. UBS upgraded ...
The pending deal was rumored overnight after a report from the Financial Times, spurring analysts to speculate that if true, ...
Explore more
14hon MSN
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...
22h
Stocktwits on MSNRoche Stock Slides After Failed Blood Cancer Trial With AbbVie, But Parkinson’s Therapy Progress Boosts Retail MoodShares of Roche drew increased retail attention Monday after the Swiss drugmaker said it would move its investigational ...
For the second time, a person with DMD has died of acute liver failure after being treated with the one-time gene therapy Elevidys.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results